Condition: Metastatic Head-and-neck Squamous-cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Sponsor: AVEO Pharmaceuticals, Inc.
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
This description comes directly from the study's public registry record.
Clinical Trials Office · +1.857.400.0101 · clinical@aveooncology.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| The University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| Yale School of Medicine - Smilow Cancer Hospital | New Haven, Connecticut, United States | Recruiting |
| The George Washington University | Washington D.C., District of Columbia, United States | Recruiting |
| AdventHealth Medical Group Oncology & Hematology at Orlando | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
| Mary Bird Perkins Cancer Center | Baton Rouge, Louisiana, United States | Recruiting |
| MaineHealth Institute for Research | South Portland, Maine, United States | Recruiting |
+ 100 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06064877